A clinical trial to investigate ARV-110 in patients with metastatic castration-resistant prostate cancer
Phase of Trial: Phase I
Latest Information Update: 04 Jan 2019
At a glance
- Drugs ARV-110 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 04 Jan 2019 According to an Arvinas media release, the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug application (IND) for ARV-110 and enrollment in this trial is expected to begin in the first quarter of 2019.
- 06 Nov 2017 New trial record
- 02 Nov 2017 According to an Arvinas media release, this trial is expected to begin in the second half of 2018.